Calcific Uremic Arteriolopathy: A Case Series and Review from an Inner-City Tertiary University Center in End-Stage Renal Disease Patients on Renal Replacement Therapy

Table 1

Baseline characteristics and biochemical lab values: (n = 24) unless noted.

Patient variables	Frequency (%)
Gender
Male	6 (25%)
Female	18 (75%)
Age group (years)
<40	4 (16.7%)
40–60	10 (41.7%)
>60	10 (41.7%)
Ethnicity
African american	22 (91.7%)
Caucasian	2 (2.3%)
Mode of renal replacement therapy
Hemodialysis	21 (87.5%)
Peritoneal dialysis	1 (4.2%)
Renal transplant	2 (8.3%)
ESRD etiology
Diabetes	13 (54.2%)
Hypertension	8 (33.3%)
Others	3 (12.3%)
Calcium level (mg/dl)
Ca > 8.5	17 (70.8%)
Ca < 8.5	7 (29.2%)
Phosphate level (mg/dl)
Ph > 6.5	9(37.5%)
Ph < 6.5	15(62.5%)
Calcium-phosphate product level (mg^2/dl^2)
CaPP > 55	10 (41.7%)
CaPP < 55	14 (58.3%)
Parathyroid hormone level (pg/ml)
PTH > 600	9 (37.5%)
PTH < 600	15 (62.5%)
Ferritin level (μg/l) (n = 20)
Ferritin > 500	14 (58.3%)
Ferritin < 500	6 (25%)
Transferrin saturation (%) (n = 20)
T.sat > 20%	14 (58.3%)
T.sat < 20%	6 (25%)

Ca: serum calcium, Ph: serum phosphorus, CaPP: serum calcium-phosphorus products, PTH: serum parathyroid hormone, T.Sat: transferrin saturation. 4 cases were missed to follow-up of transferrin saturation and ferritin levels.